Associated Genetic Biomarkers

Overview

Hematopoietic and lymphoid malignancys most frequently harbor alterations in TET2, TP53, DNMT3A, ASXL1, and JAK2 [2].

Most Commonly Altered Genes in Hematopoietic and Lymphoid Malignancy

TP53 Mutation, TP53 Missense, TP53 c.217-c.1178 Missense, DNMT3A Mutation, and TET2 Mutation are the most common alterations in hematopoietic and lymphoid malignancy [2].

Top Alterations in Hematopoietic and Lymphoid Malignancy

Significant Genes in Hematopoietic and Lymphoid Malignancy

AFF1 +

AKT1 +

AKT2 +

AKT3 +

BCL2 +

BCL6 +

CRKL +

EGFR +

ELL +

ERBB2 +

FGFR1 +

IDH1 +

IRS2 +

KIT +

KMT2A +

MECOM +

MET +

MLF1 +

MLLT1 +

MLLT10 +

MLLT3 +

MLLT4 +

MTOR +

MYC +

NPM1 +

NTRK1 +

PDGFRA +

PIK3CA +

PIK3CG +

PIK3R1 +

PIK3R2 +

PTEN +

RICTOR +

RNF43 +

RPN1 +

RPTOR +

TSC1 +

TSC2 +

Disease Details

Parent(s)
Hematopoietic and Lymphoid System Neoplasm
Children
Monomorphic Post-Transplant Lymphoproliferative Disorder, Lymphoma, Leukemia, Spleen Cancer, Polymorphic Post-Transplant Lymphoproliferative Disorder, Malignant Bone Marrow Neoplasm, Malignant Lymph Node Neoplasm, Splenic B-Cell Lymphoma/Leukemia, Unclassifiable, Lymphangiosarcoma, Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of PDGFRA/PDGFRAB or FGFR1 or PCM1-JAK2, and Malignant Mastocytosis

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.